The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
News|Articles|August 3, 2026
8 Nephrology Headlines You Missed in July 2026
Author(s)Alex Hillenbrand
Fact checked by: Chelsie Derman
Nephrology in July 2026: FDA approvals for atacicept, iptacopan, and Furoscix in IgAN/CKD, plus new IgAN and CKD trial data.
Advertisement
Advertisement
July was a landmark month for nephrology, headlined by a wave of
Related to this article
Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.
Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.
A principal healthcare consultant and study co-author shares his own decade-long path to an IgA nephropathy diagnosis and transplant.
ESC and ERA issue the first dedicated guideline on managing cardiovascular disease alongside chronic kidney disease, via a “STAMP on CKD” framework.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.
Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.
Advertisement
Advertisement